Atorvastatin

Generic Name: Atorvastatin

Brand Names: Atorvaliq, Caduet, Lipitor, Lypqozet

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₅FN_₂O_₅

CAS Number: 134523-00-5

Unique Ingredient Identifier: A0JWA85V8F

Background: Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication: Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions: Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures

Associated Therapies: -

Clinical Trials

Could Early Atorvastatin Offer Anti Inflammatory Effects Upon Brain in Traumatic Head Injury?

Not Applicable

Completed

Conditions: Traumatic Brain Injury

Interventions: Other: placebo
Drug: Atorvastatin

First Posted Date: 2021-01-22

Last Posted Date: 2022-07-01

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT04718155

Locations: 🇪🇬
Emad Zarief Kamel Said, Assiut, Egypt

Anti-inflmmation Treatment in Mood Disorder and Deep Learning Prediction Model

Phase 4

Conditions: Mood Disorder

Interventions: Drug: Atorvastatin
Drug: Aspirin

First Posted Date: 2020-12-28

Last Posted Date: 2020-12-28

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 180

Registration Number: NCT04685642

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Statins for the Treatment of NASH

Phase 2

Recruiting

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: Atorvastatin

First Posted Date: 2020-12-22

Last Posted Date: 2024-04-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 70

Registration Number: NCT04679376

Locations: 🇺🇸
Mayo Clinic Minnesota, Rochester, Minnesota, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

The Role of Statins in the Prevention of Contrast-induced Acute Kidney Injury in Patients With Cardiovascular Diseases

Not Applicable

Completed

Conditions: Contrast-induced Acute Kidney Injury
Cardiovascular Diseases

Interventions: Drug: Atorvastatin

First Posted Date: 2020-12-14

Last Posted Date: 2023-01-26

Lead Sponsor: I.M. Sechenov First Moscow State Medical University

Target Recruit Count: 150

Registration Number: NCT04666389

Locations: 🇷🇺
Sechenov University, Moscow, Russian Federation

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Atorvastatin
Drug: Pravastatin
Drug: Rosuvastatin
Drug: Filgotinib

First Posted Date: 2020-10-29

Last Posted Date: 2022-06-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 27

Registration Number: NCT04608344

Locations: 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

Phase 3

Terminated

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: Atorvastatin/Perindopril
Drug: Atorvastatin
Drug: Perindopril

First Posted Date: 2020-10-19

Last Posted Date: 2023-10-18

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 146

Registration Number: NCT04591808

Locations: 🇺🇦
Medical center ''CONSILIUM MEDICAL'', Kyiv, Ukraine
🇺🇦
Private Small-Scale Enterprise Medical Center "Pulse", Vinnytsya, Ukraine
🇷🇺
Saint Petersburg state budgetary institution of healthcare "City policlinic #109", Saint Petersburg, Russian Federation

and more 40 locations